Jade Biosciences, Inc. (JBIO) is a pre-revenue clinical-stage biopharmaceutical company with no approved products, no inventory, and no accounts receivable. The liquidation posture is modestly positive under any reasonable haircut scenario, driven entirely by a liquid asset base dominated by cash and short-term investment securities. As of March 31, 2026, total assets are $319.4M against total liabilities of $23.0M, yielding book equity of $296.5M. Under liquidation haircuts, recoverable assets approximate: cash $55.1M at 100%; short-term investments (available-for-sale debt securities) $256.2M at approximately 95-100% given the nature of marketable securities; prepaid and other current assets $7.2M at a nominal recovery of perhaps 50%; PP&E net $157K at 50-70%; ROU asset $690K at 0% (lease obligations survive); intangibles/goodwill $0 (none carried). Estimated haircut asset pool: approximately $310-315M. Total liabilities at face value including operating lease present value ($808K) sum to $23.0M. Net recovery to equity on a liquidation basis is therefore approximately $287-292M, comfortably positive. The MFFAIS CLV/LLV/OLV of $32.1M appears materially understated relative to the balance sheet; the discrepancy likely reflects model assumptions about burn rate or probability-weighted scenario haircuts applied outside the strict balance-sheet liquidation methodology used here. The prior filing provided (10-K for FY2025) confirms the company completed its reverse merger and public listing in 2025, raised capital through PIPE transactions totaling substantial proceeds, and began the quarter with roughly $88.4M in cash (implied by the $33.4M cash decrease to end at $55.1M). The burn rate for Q1 2026 was approximately $24.1M in operating cash outflow plus $73.9M in investment purchases net of $65.4M in proceeds, indicating active deployment of capital into the securities portfolio. Operating losses of $43.4M in Q1 2026 alone, with R&D of $36.1M and G&A of $7.4M, will rapidly erode the liquid asset base. At current quarterly burn of ~$24M in operating cash, the company has approximately 2.3 quarters of operating runway from cash alone, or substantially longer when including the short-term securities portfolio. A $200M ATM facility was established May 7, 2026 (post-period), which if utilized would materially extend runway but has not yet been drawn. The accumulated deficit stands at $214.8M at period end. The filing does not separately disclose contractual manufacturing commitments (CMO obligations) in XBRL, though the MD&A and risk factors discuss material reliance on WuXi Biologics and other foreign CMOs; any wind-up liability for these contracts would reduce the liquidation recovery but amounts are not disclosed. The Paragon license agreement obligations (milestone and royalty payments) would similarly need to be settled or rejected in a wind-up; face value of outstanding milestones is not separately tagged in XBRL.
▼ Community Notes